1. Home
  2. CVKD vs LUCY Comparison

CVKD vs LUCY Comparison

Compare CVKD & LUCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cadrenal Therapeutics Inc.

CVKD

Cadrenal Therapeutics Inc.

HOLD

Current Price

$5.19

Market Cap

13.8M

Sector

Health Care

ML Signal

HOLD

Logo Innovative Eyewear Inc.

LUCY

Innovative Eyewear Inc.

HOLD

Current Price

$0.98

Market Cap

5.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CVKD
LUCY
Founded
2022
2017
Country
United States
United States
Employees
N/A
11
Industry
Medicinal Chemicals and Botanical Products
Ophthalmic Goods
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.8M
5.8M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
CVKD
LUCY
Price
$5.19
$0.98
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$13.00
N/A
AVG Volume (30 Days)
66.1K
79.8K
Earning Date
05-08-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
23.94
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$175.92
Revenue Next Year
N/A
$205.56
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.21
$0.95
52 Week High
$15.99
$3.54

Technical Indicators

Market Signals
Indicator
CVKD
LUCY
Relative Strength Index (RSI) 42.02 30.50
Support Level $4.91 N/A
Resistance Level $6.09 $1.19
Average True Range (ATR) 0.74 0.04
MACD -0.09 -0.01
Stochastic Oscillator 3.56 1.09

Price Performance

Historical Comparison
CVKD
LUCY

About CVKD Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.

About LUCY Innovative Eyewear Inc.

Innovative Eyewear Inc is engaged in developing and selling eyeglasses and sunglasses, which are designed to allow customers to remain connected to their digital lives, while also offering prescription eyewear and sun protection. Its products include Lucyd Lyte, Nautica, Eddie Bauer, Lucyd Armor line, and Reebok.

Share on Social Networks: